| Nevada | 86-1005291 | |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| 80 Eighth Avenue New York, New York | | 10011 |
| (Address of principal executive offices) | | (Zip Code) |
| | | |
| Registrant’s telephone number, including area code | | (212) 373-5895 |
|
Title of Each Class
|
Trading Symbol(s)
|
Name of Each Exchange on Which Registered
|
|
None
|
None
|
None
|
| Page | |||
| 4 | |||
|
ITEM 1
|
4 | ||
|
ITEM 1A
|
9 | ||
|
ITEM 1B
|
22 | ||
|
ITEM 1C
|
22 | ||
|
ITEM 2
|
23 | ||
|
ITEM 3
|
23 | ||
|
ITEM 4
|
24 | ||
| 25 | |||
|
ITEM 5
|
25 | ||
|
ITEM 6
|
25 | ||
|
ITEM 7
|
25 | ||
|
ITEM 7A
|
36 | ||
|
ITEM 8
|
36 | ||
|
ITEM 9
|
36 | ||
|
ITEM 9A
|
36 | ||
|
ITEM 9B
|
37 | ||
|
ITEM 9C
|
37 | ||
| 38 | |||
|
ITEM 10
|
38 | ||
|
ITEM 11
|
43 | ||
|
ITEM 12
|
45 | ||
|
ITEM 13
|
47 | ||
|
ITEM 14
|
47 | ||
| 48 | |||
|
ITEM 15
|
48 | ||
|
ITEM 16
|
51 | ||
| 52 | |||
| Fiscal Year 2025 | Fiscal Year 2024 | |||||||||||||||
|
Fiscal Quarter
|
High
|
Low
|
High
|
Low
| ||||||||||||
|
First Quarter, ended December 31,
|
$ | 37.50 | $ | 30.50 | $ | 27.00 | $ | 20.51 | ||||||||
|
Second Quarter, ended March 31,
|
$ | 40.00 | $ | 27.00 | $ | 41.02 | $ | 23.01 | ||||||||
|
Third Quarter, ended June 30,
|
$ | 34.00 | $ | 25.47 | $ | 42.00 | $ | 24.00 | ||||||||
|
Fourth Quarter, ended September 30,
|
$ | 41.00 | $ | 25.47 | $ | 42.01 | $ | 30.00 | ||||||||
|
2025
|
2024
| |||||||
|
Revenues
|
$ | 207,443 | $ | 183,184 | ||||
|
Forwarding expenses and cost of revenues
|
142,450 | 124,800 | ||||||
|
Gross profit
|
64,993 | 58,384 | ||||||
|
Operating expenses
|
58,559 | 54,626 | ||||||
|
Income from operations
|
$ | 6,434 | $ | 3,758 | ||||
|
Net income
|
$ | 5,657 | $ | 551 | ||||
|
Adjusted operating income (1)
|
$ | 10,546 | $ | 6,720 |
|
2025
|
2024
| |||||||
|
Income from operations
|
$ | 6,434 | $ | 3,758 | ||||
|
Amortization of intangible assets
|
2,688 | 2,299 | ||||||
|
Stock-based compensation
|
490 | 321 | ||||||
|
Cost recognized on sale of acquired inventory
|
934 | 342 | ||||||
|
Adjusted operating income
|
$ | 10,546 | $ | 6,720 |
|
2025
|
2024
| |||||||
|
Revenues
|
$ | 183,823 | $ | 159,958 | ||||
|
Forwarding expense
|
134,760 | 117,501 | ||||||
|
Gross profit
|
$ | 49,063 | $ | 42,457 | ||||
|
Gross profit margin
|
26.7 | % | 26.5 | % | ||||
|
Selling, general and administrative expenses
|
$ | 38,680 | $ | 37,057 | ||||
|
Income from operations
|
$ | 10,383 | $ | 5,400 |
|
2025
|
2024
| |||||||
|
Revenues
|
$ | 14,126 | $ | 13,154 | ||||
|
Cost of sales
|
2,327 | 2,296 | ||||||
|
Cost recognized upon sale of acquired inventory
|
934 | 342 | ||||||
|
Gross profit
|
$ | 10,865 | $ | 10,516 | ||||
|
Gross profit margin
|
76.9 | % | 79.9 | % | ||||
|
Selling, general and administrative expenses
|
$ | 8,402 | $ | 7,216 | ||||
|
Income from operations
|
$ | 2,463 | $ | 3,300 |
|
2025
|
2024
| |||||||
|
Revenues
|
$ | 9,494 | $ | 10,072 | ||||
|
Cost of sales
|
4,429 | 4,661 | ||||||
|
Gross profit
|
$ | 5,065 | $ | 5,411 | ||||
|
Gross profit margin
|
53.3 | % | 53.7 | % | ||||
|
Selling, general and administrative expenses
|
$ | 3,253 | $ | 3,129 | ||||
|
Income from operations
|
$ | 1,812 | $ | 2,282 |
| Years Ended September 30, |
||||||||
|
2025
|
2024
| |||||||
|
(In thousands)
|
||||||||
|
Total income from operating segments
|
$ | 14,657 | $ | 10,982 | ||||
|
Corporate expenses
|
(5,045 | ) | (4,620 | ) | ||||
|
Amortization expense
|
(2,688 | ) | (2,299 | ) | ||||
|
Stock-based compensation - Corporate
|
(490 | ) | (305 | ) | ||||
|
Total Corporate expenses
|
(8,223 | ) | (7,224 | ) | ||||
|
Interest expense
|
(2,073 | ) | (2,318 | ) | ||||
| Other income (expense) | 2,518 | (346 | ) | |||||
|
Net income before taxes
|
6,879 | 1,094 | ||||||
|
Income tax expense
|
(1,222 | ) | (543 | ) | ||||
|
Net Income
|
5,657 | 551 | ||||||
|
Preferred stock dividends
|
(384 | ) | (328 | ) | ||||
|
Non-controlling interest dividends
|
(243 | ) | — | |||||
|
Net Income Available to Common Stockholders
|
$ | 5,030 | $ | 223 | ||||
| September 30, | ||||||||
| 2025 | 2024 | |||||||
|
Total Debt
|
$ | 8,077 | $ | 4,304 | ||||
|
Less Current Portion
|
(911 | ) | (1,276 | ) | ||||
|
Long-term Portion
|
$ | 7,166 | $ | 3,028 | ||||
|
Fiscal Year 2026
|
$ | 911 | ||
|
Fiscal Year 2027
|
911 | |||
|
Fiscal Year 2028
|
911 | |||
|
Fiscal Year 2029
|
911 | |||
|
Fiscal Year 2030
|
4,433 | |||
| $ | 8,077 |
|
Name
|
Age |
Position
|
||
|
Darren C. Seirer
|
51 |
Board Chairman, President and Chief Executive Officer
|
||
|
John Eidinger
|
45 |
Board Vice Chairman
|
||
|
Gerard van Kesteren
|
76 |
Director, Chair of Audit Committee, Senior Advisor to Logistics
|
||
|
Karen M. Ryan
|
61 |
Director, Chair of Compensation Committee, Senior Advisor to Life Sciences
|
||
|
Gregory J. Melsen
|
73 |
Director, Chair of Nominating and Corporate Governance Committee
|
||
|
John J. Gonzalez, II
|
75 |
Director, Senior Advisor for Mergers and Acquisitions
|
||
|
Gregory B. Graves
|
65 |
Director
|
||
|
Nathan C. Shandy
|
38 |
Chief Financial Officer, Treasurer and Secretary
|
|
Name
|
Fees Earned or Paid in Cash(1) |
Option Awards(2) |
All Other Compensation | Total | ||||||||||||
|
John J. Gonzalez, II
|
$ | 40,000 | $ | 49,656 | $ | 109,000 | (3) | $ | 198,656 | |||||||
|
Gerard van Kesteren
|
$ | 50,000 | $ | 49,656 | $ | 50,000 | (3) | $ | 149,656 | |||||||
|
Karen M. Ryan
|
$ | 50,000 | $ | 49,656 | $ | 50,000 | (3) | $ | 149,656 | |||||||
|
Gregory J. Melsen
|
$ | 50,000 | $ | 49,656 | $ | — | $ | 99,656 | ||||||||
|
Gregory B. Graves
|
$ | 40,000 | $ | 49,656 | $ | — | $ | 89,656 |
|
Name and Principal Position
|
Year |
Base Salary ($) | Bonus ($) |
All Other Comp. ($) | Total ($) | |||||||||||||
|
Darren C. Seirer, Chief Executive Officer and President
|
2025
|
100,000 | — | 1,252 | (1) | 101,252 | ||||||||||||
|
2024
|
100,000 | — | 1,252 | 101,252 | ||||||||||||||
|
John Eidinger, Vice Chairman
|
2025
|
200,000 | — | — | 200,000 | |||||||||||||
|
2024
|
144,000 | — | — | 144,000 | ||||||||||||||
|
Joseph R. Ferrara, Former Principal Financial Officer, Treasurer and Secretary(2)
|
2025
|
250,000 | 115,000 | 10,962 | 375,962 | |||||||||||||
|
2024
|
155,754 | 25,000 | 3,254 | 184,008 | ||||||||||||||
|
Nathan C. Shandy, Chief Financial Officer, Treasurer and Secretary (3)
|
2025
|
245,409 | 25,944 | 7,683 | 279,036 |
|
Name and address of Beneficial Owner (1)
|
Shares Beneficially Owned |
Percent of Class | ||||||
|
Oaxaca Group L.L.C. (2)
|
485,302 | 40.9 | % | |||||
|
John Eidinger
|
186,704 | 15.7 | % | |||||
|
John J. Gonzalez, II (3)
|
103,569 | 8.6 | % | |||||
|
van Kesteren Foundation (4)
|
85,000 | 7.2 | % | |||||
|
Brendan Killackey
|
61,300 | 5.2 | % |
|
Name of Beneficial Owner
|
Shares Beneficially Owned |
Percent of Class | ||||||
| Darren C. Seirer(3) | 439,993 | 37.1 | % | |||||
|
John Eidinger
|
186,704 | 15.7 | % | |||||
|
John J. Gonzalez, II (1)
|
103,569 | 8.6 | % | |||||
|
Gerard van Kesteren (1)
|
45,499 | 3.8 | % | |||||
|
Gregory J. Melsen (1)
|
19,375 | 1.6 | % | |||||
|
Karen M. Ryan (1)
|
14,444 | 1.2 | % | |||||
|
Gregory B. Graves (2)
|
10,507 | 1.0 | % | |||||
|
Nathan Shandy
|
100 | * | ||||||
|
All directors and executive officers as a group (8 persons)
|
820,191 | 69.0 | % |
| Column A | Column B | Column C | ||||||||||
|
Plan Category: Equity Compensation plans not approved by security holders:
|
Number of securities
to be issued, upon exercise of outstanding options, warrants and rights |
Weighted-average
exercise price of outstanding options, warrants and rights |
Number of securities remaining available for future issuance under equity compensation plans | |||||||||
|
2013 Non-Qualified Stock Option Plan (1)
|
3,121 | $ | 8.01 | 39,201 | ||||||||
|
Amended and Restated 2017 Equity Incentive Plan (2)
|
59,372 | $ | 29.42 | 44,754 | ||||||||
|
Total
|
62,493 | $ | 25.31 | 83,955 |
| Year End September 30, | ||||||||
|
Fee Category
|
2025 | 2024 | ||||||
|
Audit Fees
|
$ | 378,740 | $ | 350,000 | ||||
|
Audit-Related Fees
|
41,000 | 16,582 | ||||||
|
Tax Fees
|
— | — | ||||||
|
Total Fees
|
$ | 419,740 | $ | 366,582 | ||||
| Exhibit No. |
Description | |
| * 2.1 | Stock Purchase and Sale Agreement, dated July 1, 2022, between Janel Corporation and Rubicon Technology, Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed July 5, 2022) | |
| * 2.2 | Contribution Agreement, dated as of August 20, 2025, between Janel Corporation and Rubicon Technology, Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed August 22, 2025) | |
| 3.1 | Articles of Incorporation of Wine Systems Design, Inc. (predecessor name) (incorporated by reference to Exhibit 3A to Wine Systems Design, Inc. (predecessor name) Registration Statement on Form SB-2 filed May 10, 2001) | |
| 3.2 |
Amended and Restated By-Laws of Janel Corporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed November 1, 2013)
|
|
| 3.3 | Certificate of Designations of Series C Cumulative Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed August 29, 2014) | |
| 3.4 | Certificate of Change filed Pursuant to NRS 78.209 for Registrant (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed April 21, 2015) | |
| 3.5 | Certificate of Amendment to Articles of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed April 21, 2015) | |
| 3.6 | Amendment to Certificate of Designation After Issuance of Class or Series pursuant to NRS 78.1955 for Series C Cumulative Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed March 25, 2016) | |
| 3.7 | Amendment to Certificate of Designation After Issuance of Class or Series pursuant to NRS 78.1955 for Series C Cumulative Preferred Stock (incorporated by reference to Exhibit 3.7 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017) | |
| 3.8 | Amendment to Certificate of Designation After Issuance of Class or Series pursuant to NRS 78.1955 for Series C Cumulative Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K/A filed October 17, 2017) | |
| 3.9 | Amendment to Certificate of Designation After Issuance of Class or Series pursuant to NRS 78.1955 for Series C Cumulative Preferred Stock (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on October 5, 2021) | |
| 3.10 | Certificate, Amendment or Withdrawal of Designation pursuant to NRS 78.1955 with respect to Series C Cumulative Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on April 5, 2022) | |
| 4.1 | Description of Registrant’s Securities (filed herewith) | |
| † 10.1 | Janel World Trade, Ltd. 2013 Non-Qualified Stock Option Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed November 1, 2013) | |
| 10.2 | Credit Agreement, effective as of February 29, 2016, by and between Indco, Inc. and First Merchants Bank (incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K filed March 25, 2016) | |
| 10.3 | Security Agreement, effective as of February 29, 2016, made by Indco and the Company, Inc. for the benefit of First Merchants Bank (incorporated by reference to Exhibit 10.8 to the Company’s Current Report on Form 8-K filed March 25, 2016) | |
| 10.4 | Continuing Guaranty Agreement, effective as of February 29, 2016, made by Janel Corporation for the benefit of First Merchants Bank (incorporated by reference to Exhibit 10.9 to the Company’s Current Report on Form 8-K filed March 25, 2016) |
| † 10.5 | Restricted Stock Award Agreement between Janel Corporation and Gerard van Kesteren dated May 12, 2017 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed September 5, 2017) | |
| 10.6 | Business Loan Agreement, dated June 14, 2018, by and between AB Merger Sub, Inc. and First Northern Bank of Dixon (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed June 27, 2018) | |
| 10.7 | Promissory Note, dated June 14, 2018, made by AB Merger Sub, Inc. payable to First Northern Bank of Dixon (incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed June 27, 2018) | |
| 10.8 | Deed of Trust, dated June 14, 2018, by Antibodies Incorporated, as Trustor (incorporated by reference to Exhibit 10.3 of the Company’s Current Report on Form 8-K filed June 27, 2018) | |
| 10.9 | Commercial Guaranty, dated June 14, 2018, from Janel Corporation (as Guarantor) to First Northern Bank of Dixon (incorporated by reference to Exhibit 10.4 of the Company’s Current Report on Form 8-K filed June 27, 2018) | |
| 10.10 | Amendment No. 1 to Credit Agreement, effective as of August 30, 2019, by and between Indco, Inc. and First Merchants Bank (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed on September 6, 2019) | |
| 10.11 | Term Loan Promissory Note, effective as of August 30, 2019, made by Indco, Inc. payable to First Merchants Bank (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on September 6, 2019) | |
| 10.12 | Revolving Loan Promissory Note, effective as of August 30, 2019, made by Indco, Inc. payable to First Merchants Bank (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on September 6, 2019) | |
| 10.13 | Pledge Agreement, effective as of August 30, 2019, by Janel Corporation to First Merchants Bank (incorporated by reference to Exhibit 10.4 of the Company’s Current Report on Form 8-K filed on September 6, 2019) | |
| † 10.14 | Consulting Agreement, dated February 26, 2017, between Janel Corporation and John J. Gonzalez, II (incorporated by reference to Exhibit 10.30 of the Company’s Form 10-K for the year ended September 30, 2018, filed on July 26, 2019) | |
| † 10.15 | Consulting Agreement, dated September 28, 2016, between Janel Corporation and Gerard van Kesteren (incorporated by reference to Exhibit 10.31 of the Company’s Form 10-K for the year ended September 30, 2018, filed on July 26, 2019) | |
| 10.16 | Amendment No. 2 to Credit Agreement effective as of July 1, 2020, by and between Indco Inc. and First Merchants Bank (incorporated by reference to Exhibit 10.39 of the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2020) | |
| 10.17 | Amended and Restated Loan and Security Agreement, by and among Santander Bank, N.A., as lender, and Janel Group, Inc., Expedited Logistics and Freight Services, LLC, a Texas limited liability company, and ELFS Brokerage, LLC (collectively as borrowers) and Janel Corporation and Expedited Logistics and Freight Services, LLC, an Oklahoma limited liability company, as loan party obligors dated September 21, 2021 (incorporated by reference to Exhibit 10.44 of the Company’s Annual Report on Form 10-K for the year ended September 30, 2021) | |
| 10.18 | First Amendment to Amended and Restated Loan and Security Agreement between (incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022) | |
| 10.19 | Consent, Waiver and Second Amendment to Amended and Restated Loan Agreement, dated as of July 13, 2022, by and among Santander Bank, N.A., Janel Group, Inc., Expedited Logistics and Freight Services, LLC, ELFS Brokerage LLC, Janel Corporation and Expedited Logistics and Freight Services, LLC (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed on July 13, 2022) | |
| 10.20 | Form letter purchase agreement, dated March 31, 2022, between the Company and holders of Series C Stock (incorporated by reference to Exhibit 10.2 of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022) | |
| 10.21 | Amended and Restated 2017 Janel Corporation Equity Incentive Plan dated September 21, 2021 (incorporated by reference to Exhibit 10.45 of the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2021) | |
| 10.22 | Subscription Agreement for sale of Series C Preferred Stock dated as of September 30, 2021 between Janel Corporation and Oaxaca Group LLC (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed on October 5, 2021) | |
| 10.23 | Amendment No. 3 to Credit Agreement effective as of August 1, 2022 entered into by and among Indco, Inc., and First Merchants Bank (incorporated by reference to Exhibit 10.23 of the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2022) | |
| 10.24 | Third Amendment to Amended and Restated Loan and Security Agreement, by and among Santander Bank, N.A., as lender, and Janel Group, Inc., Expedited Logistics and Freight Services, LLC, a Texas limited liability company, and ELFS Brokerage, LLC (collectively as borrowers) and Janel Corporation and Expedited Logistics and Freight Services, LLC, an Oklahoma limited liability company, as loan party obligors dated January 30, 2023 (incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2022) |
| 10.25 | Amended and Restated Credit Agreement, by and among Indco, Inc., Antibodies Incorporated, Aves Labs, Inc., PhosphoSolutions LLC, Immunochemistry Technologies LLC, ECM Biosciences, LLC, Stephen Hall PhD LTD, ImmunoBioScience Corp., (collectively as borrowers), and each individually, a “Borrower”), and First Merchants Bank dated April 25, 2023 (incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023). | |
| 10.26 | First Amendment to Amended and Restated Credit Agreement, by and among Indco, Inc. a Tennessee corporation, Antibodies Incorporated, a California corporation, Aves Labs, Inc., an Oregon corporation, PhosphoSolutions LLC, a Nevada limited liability company, Immunochemistry Technologies LLC, a Minnesota limited liability company, ECM Biosciences, LLC, a Kentucky limited liability company, Stephen Hall, PHD LTD, an Indiana corporation, ImmunoBioScience Corp., a Washington corporation (collectively as borrowers) and Janel Corporation, a Nevada corporation, as guarantor, and First Merchants Bank, as bank, dated January 10, 2024 (incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024) | |
| 10.27 | Fourth Amendment to Amended and Restated Loan and Security Agreement, by and among Santander Bank, N.A., as lender, and Janel Group, Inc., Expedited Logistics and Freight Services, LLC, and ELFS Brokerage, LLC (collectively as borrowers) and Janel Corporation and Expedited Logistics and Freight Services, LLC, as loan party obligors dated April 25, 2023 (incorporated by reference to Exhibit 10.2 of the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023). | |
| 10.28 | Fifth Amendment to Amended and Restated Loan and Security Agreement, by and among Santander Bank, N.A., as lender, and Janel Group, Inc., Expedited Logistics and Freight Services, LLC, and ELFS Brokerage, LLC (collectively as borrowers) and Janel Corporation and Expedited Logistics and Freight Services, LLC, as loan party obligors dated August 22, 2023 (incorporated by reference to Exhibit 10.27 of the Company’s Annual Report on Form 10-K for the year ended September 30, 2023). | |
| 10.29 | Sixth Amendment to Amended and Restated Loan and Security Agreement, by and among Santander Bank, N.A., as lender, and Janel Group, Inc., Expedited Logistics and Freight Services, LLC, and ELFS Brokerage, LLC (collectively as borrowers) and Janel Corporation and Expedited Logistics and Freight Services, LLC, as loan party obligors dated December 21, 2023 (incorporated by reference to Exhibit 10.2 of the Company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2023). | |
| 10.30 | Consent, Joinder and Seventh Amendment to Amended and Restated Loan and Security Agreement, dated as of June 5, 2024, by and among Santander Bank, N.A., as lender, Janel Group, Inc., Expedited Logistics and Freight Services, LLC, ELFS Brokerage LLC, Janel Corporation, Expedited Logistics and Freight Services, LLC and Airschott, Inc (incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q for the quarter June 30, 2024) | |
| 10.31 | Membership Interest Purchase Agreement dated September 21, 2021, by and among Janel Group, Expedited Logistics and Freight Services, LLC and former shareholders of Expedited Logistics and Freight Services, LLC (incorporated by reference to Exhibit 10.43 of the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2021) | |
| 10.32 | Amendment, dated December 1, 2023, to Membership Interest Purchase Agreement dated September 21, 2021, by and among Janel Group, Expedited Logistics and Freight Services, LLC and former shareholders of Expedited Logistics and Freight Services, LLC (incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2023) | |
| † 10.34 | Consulting Agreement, dated July 3, 2024, between Janel Corporation and Karen Ryan (incorporated by reference to Exhibit 10.34 of the Company’s Annual Report on Form 10-K for the year ended September 30, 2024) | |
| 10.35 | Eighth Amendment to Amended and Restated Loan and Security Agreement, by and among Santander Bank, N.A., as lender, and Janel Group, Inc., Expedited Logistics and Freight Services, LLC, ELFS Brokerage, LLC, and Airschott, Inc. (collectively as borrowers) and Janel Corporation and Expedited Logistics and Freight Services, LLC, as loan party obligors dated November 1, 2024 (incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2024). | |
| 10.36 | Second Amendment to Amended and Restated Acquisition Note, dated November 22, 2024, by and among Indco, Inc., Antibodies Incorporated, Aves Labs, Inc., PhosphoSolutions LLC, Immunochemistry Technologies LLC, ECM Biosciences, LLC, ImmunoBioScience Corp, and ViraQuest, Inc., as borrowers, hereby jointly and severally promise to pay to the order of First Merchants as Lender (incorporated by reference to Exhibit 10.2a of the Company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2024). | |
| 10.37 | Second Amendment to Amended and Restated Revolving Note dated November 22, 2024, by and among Indco, Inc., Antibodies Incorporated, Aves Labs, Inc., PhosphoSolutions LLC, Immunochemistry Technologies LLC, ECM Biosciences, LLC, ImmunoBioScience Corp, and ViraQuest, Inc., as borrowers, hereby jointly and severally promise to pay to the order of First Merchants as Lender (incorporated by reference to Exhibit 10.2b of the Company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2024). | |
| 10.38 | Second Amendment to Amended and Restated Term A Note dated November 22, 2024, by and among Indco, Inc., Antibodies Incorporated, Aves Labs, Inc., PhosphoSolutions LLC, Immunochemistry Technologies LLC, ECM Biosciences, LLC, ImmunoBioScience Corp, and ViraQuest, Inc., as borrowers, hereby jointly and severally promise to pay to the order of First Merchants as Lender (incorporated by reference to Exhibit 10.2c of the Company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2024). |
| 10.39 | Second Amendment to Amended and Restated Term B Note dated November 22, 2024, by and among Indco, Inc., Antibodies Incorporated, Aves Labs, Inc., PhosphoSolutions LLC, Immunochemistry Technologies LLC, ECM Biosciences, LLC, ImmunoBioScience Corp, and ViraQuest, Inc., as borrowers, hereby jointly and severally promise to pay to the order of First Merchants as Lender (incorporated by reference to Exhibit 10.2d of the Company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2024) | |
| 10.40 | Third Amendment to Amended and Restated Term A Note dated July 1, 2025, by and among Indco, Inc., Antibodies Incorporated, Aves Labs, Inc., PhosphoSolutions LLC, Immunochemistry Technologies LLC, ImmunoBioScience Corp, Biosensis, LLC and Janel Corporation, as borrowers, hereby jointly and severally promise to pay to the order of First Merchants as Lender (filed herewith). | |
| 10.41 |
Third Amendment to Amended and Restated
Term B Note dated July 1, 2025, by and among Indco, Inc., Antibodies
Incorporated, Aves Labs, Inc., PhosphoSolutions LLC, Immunochemistry
Technologies LLC, ImmunoBioScience Corp, Biosensis, LLC and Janel Corporation,
as borrowers, hereby jointly and severally promise to pay to the order of First
Merchants as Lender (filed herewith).
|
|
| 10.42 |
Third Amendment to Amended and Restated Revolving
Note dated July 1, 2025, by and among Indco, Inc., Antibodies Incorporated,
Aves Labs, Inc., PhosphoSolutions LLC, Immunochemistry Technologies LLC,
ImmunoBioScience Corp, Biosensis, LLC and Janel Corporation, as borrowers,
hereby jointly and severally promise to pay to the order of First Merchants as
Lender (filed herewith).
|
|
| 10.43 |
Second Amendment to Acquisition Note dated
July 1, 2025, by and among Indco, Inc., Antibodies Incorporated, Aves Labs,
Inc., PhosphoSolutions LLC, Immunochemistry Technologies LLC, ImmunoBioScience
Corp, Biosensis, LLC and Janel Corporation, as borrowers, hereby jointly and
severally promise to pay to the order of First Merchants as Lender (filed
herewith).
|
|
| 10.44 |
Third Amendment to Amended and Restated
Credit Agreement and Joinder dated July 1, 2025, by and among Indco, Inc.,
Antibodies Incorporated, Aves Labs, Inc., PhosphoSolutions LLC, Immunochemistry
Technologies LLC, ImmunoBioScience Corp, Biosensis, LLC and Janel Corporation,
as borrowers, hereby jointly and severally promise to pay to the order of First
Merchants as Lender (filed herewith).
|
|
| 10.45 | Ninth Amendment to Amended and Restated Loan and Security Agreement dated September 3, 2025, by and among Santander Bank, N.A., as lender, and Janel Group, LLC, Expedited Logistics and Freight Services, LLC, ELFS Brokerage, LLC, and Airschott, Inc. (collectively as borrowers), Interlog USA Inc. and Commerce Express, Inc. (collectively as new borrowers), and Janel Corporation and Expedited Logistics and Freight Services, LLC, as loan party obligors | |
| 19.1 |
Insider Trading Policy, effective May 2, 2024
|
|
| 21 | Subsidiaries of the Registrant (filed herewith) | |
| 23.1 | Consent of Prager Metis CPAs, LLC (filed herewith) | |
| 31.1 | Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer (filed herewith) | |
| 31.2 | Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer (filed herewith) | |
| 32.1 | Section 1350 Certification of Principal Executive Officer (furnished herewith) | |
| 32.2 | Section 1350 Certification of Principal Financial Officer (furnished herewith) | |
| 101 | Interactive data files providing financial information from the Registrant’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025 in Inline XBRL (eXtensible Business Reporting Language) pursuant to Rule 405 of Regulation S-T: (i) Consolidated Balance Sheets as of September 30, 2025 and September 30, 2024, (ii) Consolidated Statements of Operations for the years ended September 30, 2025 and 2024, (iii) Consolidated Statements of Stockholders’ Equity for the years ended September 30, 2025 and 2024, (iv) Consolidated Statements of Cash Flows for the years ended September 30, 2025 and 2024, and (v) Notes to Consolidated Financial Statements (filed herewith) | |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in the Interactive Data Files submitted as Exhibit 101) (filed herewith) |
|
|
JANEL CORPORATION
(Registrant)
|
|
|
|
|
|
|
Date: December 5, 2025
|
By:
|
/s/ Darren C. Seirer
|
|
|
Darren C. Seirer
|
|
|
|
|
|
|
|
Director, Board Chairman, President and Chief Executive Officer
(Principal Executive Officer)
|
|
|
|
|
|
|
Date: December 5, 2025
|
By:
|
/s/ Nathan C. Shandy
|
|
|
Nathan C. Shandy
|
|
|
|
|
|
|
|
Chief Financial Officer, Treasurer and Secretary
(Principal Financial and Accounting Officer)
|
|
| Signature | Title | Date | ||
|
/s/ Darren C. Seirer
|
Director, Board Chairman, President and Chief Executive Officer
|
December 5, 2025
|
||
|
Darren C. Seirer
|
||||
|
/s/ John Eidinger
|
Director, Board Vice Chairman
|
December 5, 2025
|
||
|
John Eidinger
|
||||
|
/s/ Nathan C. Shandy
|
Chief Financial Officer, Treasurer and Secretary
|
December 5, 2025
|
||
|
Nathan C. Shandy
|
||||
|
/s/ John J. Gonzalez, II
|
Director
|
December 5, 2025
|
||
|
John J. Gonzalez, II
|
||||
|
/s/ Gregory J. Melsen
|
Director
|
December 5, 2025
|
||
|
Gregory J. Melsen
|
||||
|
/s/ Karen M. Ryan
|
Director
|
December 5, 2025
|
||
|
Karen M. Ryan
|
||||
|
/s/ Gerard van Kesteren
|
Director
|
December 5, 2025
|
||
|
Gerard van Kesteren
|
||||
|
/s/ Gregory B. Graves
|
Director
|
December 5, 2025
|
||
|
Gregory B. Graves
|
| Report of Registered Independent Public Accounting Firm – Prager Metis CPAs, LLC (PCAOB ID number 273) | F-2 |
| F-3 | |
| F-4 | |
| F-5 | |
| F-6 | |
| F-7 |
| September 30, | ||||||||
| 2025 | 2024 | |||||||
| ASSETS | ||||||||
|
Current Assets:
|
||||||||
|
Cash
|
$ | 10,962 | $ | 2,888 | ||||
| Restricted cash | 1,078 | — | ||||||
|
Accounts receivable, net of allowance for doubtful accounts
|
66,489 | 33,815 | ||||||
|
Inventory, net
|
4,207 | 4,478 | ||||||
|
Prepaid expenses and other current assets
|
6,095 | 4,829 | ||||||
|
Total current assets
|
88,831 | 46,010 | ||||||
|
Property and Equipment, net
|
5,971 | 5,492 | ||||||
|
Other Assets:
|
||||||||
|
Intangible assets, net
|
30,998 | 25,117 | ||||||
|
Goodwill
|
31,592 | 23,030 | ||||||
|
Restricted cash
|
— | 194 | ||||||
|
Restricted investment
|
250 | 56 | ||||||
|
Investment in marketable securities at fair value
|
4,664 | 1,518 | ||||||
|
Operating lease right of use asset
|
7,760 | 8,621 | ||||||
|
Security deposits and other long-term assets
|
687 | 572 | ||||||
|
Total other assets
|
75,951 | 59,108 | ||||||
|
Total assets
|
$ | 170,753 | $ | 110,610 | ||||
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
|
Current Liabilities:
|
||||||||
|
Line of credit
|
$ | 3,801 | $ | 23,013 | ||||
|
Accounts payable - trade
|
98,244 | 32,000 | ||||||
|
Accrued expenses and other current liabilities
|
10,176 | 7,489 | ||||||
|
Dividends payable
|
1,649 | 2,271 | ||||||
|
Current portion of earnout
|
2,592 | 1,262 | ||||||
|
Current portion of long-term debt
|
911 | 1,276 | ||||||
|
Current portion of subordinated promissory note-related party
|
||||||||
|
Current portion of operating lease liabilities
|
2,114 | 2,419 | ||||||
|
Total current liabilities
|
120,661 | 71,358 | ||||||
|
Other Liabilities:
|
||||||||
|
Long-term debt
|
7,166 | 3,028 | ||||||
|
Long-term portion of earnout
|
1,150 | 2,119 | ||||||
|
Subordinated promissory notes-related party
|
||||||||
|
Mandatorily redeemable non-controlling interest
|
3,066 | 1,529 | ||||||
|
Deferred income taxes
|
4,547 | 2,514 | ||||||
|
Long-term operating lease liabilities
|
6,310 | 6,585 | ||||||
|
Other liabilities
|
285 | 531 | ||||||
|
Total other liabilities
|
24,290 | 19,751 | ||||||
|
Total liabilities
|
144,951 | 91,109 | ||||||
|
Stockholders' Equity:
|
||||||||
| Preferred Stock, $0.001 par value; 100,000 shares authorized |
— | — | ||||||
| Series C 30,000 shares authorized and 11,368 shares issued and outstanding at September 30, 2025 and September 30, 2024, liquidation value of $7,333 and $7,957 at September 30, 2025 and September 30, 2024, respectively |
— | — | ||||||
| Common stock, $0.001 par value; 4,500,000 shares authorized, 1,206,354 issued and 1,186,354 outstanding as of September 30, 2025 and September 30, 2024, respectively |
1 | 1 | ||||||
|
Paid-in capital
|
17,730 | 17,084 | ||||||
| Common treasury stock, at cost, 20,000 shares |
(240 | ) | (240 | ) | ||||
|
Accumulated earnings
|
8,311 | 2,656 | ||||||
|
Total stockholders' equity
|
25,802 | 19,501 | ||||||
|
Total liabilities and stockholders' equity
|
$ | 170,753 | $ | 110,610 | ||||
| Year Ended September 30, | ||||||||
| 2025 | 2024 | |||||||
|
Revenues:
|
||||||||
|
Logistics
|
$ | 183,823 | $ | 159,958 | ||||
|
Life Sciences and Manufacturing
|
23,620 | 23,226 | ||||||
|
Total Revenues
|
207,443 | 183,184 | ||||||
|
Forwarding expenses and cost of revenues:
|
||||||||
|
Forwarding expenses - Logistics
|
134,760 | 117,501 | ||||||
|
Cost of revenues - Life Sciences and Manufacturing
|
7,690 | 7,299 | ||||||
|
Total forwarding expenses and cost of revenues
|
142,450 | 124,800 | ||||||
|
Gross profit
|
64,993 | 58,384 | ||||||
|
Operating Expenses:
|
||||||||
|
Selling, general and administrative
|
55,871 | 52,327 | ||||||
|
Amortization of intangible assets
|
2,688 | 2,299 | ||||||
|
Total Operating Expenses
|
58,559 | 54,626 | ||||||
|
Income from Operations
|
6,434 | 3,758 | ||||||
|
Other Items:
|
||||||||
|
Interest expense net of interest income
|
(2,073 | ) | (2,318 | ) | ||||
|
Other income (expense)
|
2,518 | (346 | ) | |||||
|
Income Before Income Taxes
|
6,879 | 1,094 | ||||||
|
Income tax benefit (expense)
|
(1,222 | ) | (543 | ) | ||||
|
Net Income
|
5,657 | 551 | ||||||
|
Preferred stock dividends
|
(384 | ) | (328 | ) | ||||
|
Non-controlling interest dividends
|
(243 | ) | — | |||||
|
Net Income Available to Common Stockholders
|
5,030 | 223 | ||||||
|
Net income per share:
|
||||||||
|
Basic
|
4.77 | 0.46 | ||||||
|
Diluted
|
$ | 4.69 | $ | 0.45 | ||||
|
Net income per share attributable to common stockholders:
|
||||||||
|
Basic
|
4.24 | 0.19 | ||||||
|
Diluted
|
$ | 4.17 | $ | 0.18 | ||||
|
Weighted average number of shares outstanding:
|
||||||||
|
Basic
|
1,186.4 | 1,186.4 | ||||||
|
Diluted
|
1,205.4 | 1,206.2 | ||||||
| PREFERRED STOCK | COMMON STOCK | PAID-IN CAPITAL | COMMON TREASURY STOCK | ACCUMULATED EARNING (DEFICIT) | TOTAL EQUITY | |||||||||||||||||||||||||||||||
| Shares | $ | Shares | $ | $ | Shares | $ | $ | $ | ||||||||||||||||||||||||||||
|
Balance - September 30, 2023
|
11,368 | $ | — | 1,206,354 | $ | 1 | $ | 17,107 | 20,000 | $ | (240 | ) | $ | 2,105 | $ | 18,973 | ||||||||||||||||||||
|
Net Income
|
— | — | — | — | — | — | — | 551 | 551 | |||||||||||||||||||||||||||
|
Dividends to preferred stockholders
|
— | — | — | — | (328 | ) | — | — | — | (328 | ) | |||||||||||||||||||||||||
|
Stock based compensation
|
— | — | — | — | 305 | — | — | — | 305 | |||||||||||||||||||||||||||
|
Balance - September 30, 2024
|
11,368 | — | 1,206,354 | 1 | 17,084 | 20,000 | (240 | ) | 2,656 | 19,501 | ||||||||||||||||||||||||||
|
Net Income
|
— | — | — | — | — | — | — | 5,657 | 5,657 | |||||||||||||||||||||||||||
|
Dividends to preferred stockholders
|
— | — | — | — | (384 | ) | — | — | — | (384 | ) | |||||||||||||||||||||||||
|
Dividends to non-controlling interest
|
— | — | — | — | (243 | ) | — | — | — | (243 | ) | |||||||||||||||||||||||||
|
Stock based compensation
|
490 | 490 | ||||||||||||||||||||||||||||||||||
|
Stock option exercise
|
— | — | — | — | 781 | — | — | — | 781 | |||||||||||||||||||||||||||
|
Balance - September 30, 2025
|
11,368 | $ | — | 1,206,354 | $ | 1 | $ | 17,728 | 20,000 | $ | (240 | ) | $ | 8,313 | $ | 25,802 | ||||||||||||||||||||
| Year Ended September 30, | ||||||||
| 2025 | 2024 | |||||||
|
Cash Flows from Operating Activities:
|
||||||||
|
Net income
|
$ | 5,657 | $ | 551 | ||||
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
||||||||
|
Recovery of uncollectible accounts
|
80 | (37 | ) | |||||
|
Depreciation
|
645 | 551 | ||||||
|
Deferred income tax provision
|
(257 | ) | 196 | |||||
|
Amortization of intangible assets
|
2,688 | 2,299 | ||||||
|
Amortization of acquired inventory valuation
|
934 | 342 | ||||||
|
Amortization of loan costs
|
296 | 81 | ||||||
|
Stock based compensation
|
490 | 321 | ||||||
|
Unrealized (gain) loss on marketable securities
|
(3,099 | ) | 41 | |||||
|
Change in fair value of earnout
|
434 | 774 | ||||||
|
Change in fair value of mandatorily redeemable noncontrolling interest
|
385 | 964 | ||||||
|
Gain on extinguishment
|
— | (22 | ) | |||||
|
Changes in operating assets and liabilities, net of effects of acquisitions:
|
||||||||
|
Accounts receivable
|
(25,167 | ) | (4,515 | ) | ||||
|
Inventory
|
(103 | ) | 39 | |||||
|
Prepaid expenses and other current assets
|
(2,054 | ) | (250 | ) | ||||
|
Security deposits and other long-term assets
|
(638 | ) | 19 | |||||
|
Accounts payable and accrued expenses
|
62,877 | 5,296 | ||||||
|
Other liabilities
|
(102 | ) | 181 | |||||
|
Net cash provided by operating activities
|
43,066 | 6,831 | ||||||
|
Cash Flows from Investing Activities:
|
||||||||
|
Acquisition of property and equipment, net of disposals
|
(590 | ) | (1,003 | ) | ||||
|
Investment in marketable securities (net of dividends)
|
(240 | ) | (42 | ) | ||||
|
Acquisition of Indco shares
|
(1,374 | ) | — | |||||
|
Acquisitions, net of cash acquired
|
(11,925 | ) | (3,851 | ) | ||||
|
Earnout payment
|
(1,078 | ) | (740 | ) | ||||
|
Net cash used in investing activities
|
(15,207 | ) | (5,636 | ) | ||||
|
Cash Flows from Financing Activities:
|
||||||||
|
Dividends paid to preferred stockholders
|
(1,008 | ) | (84 | ) | ||||
|
Dividends paid to non-controlling interest
|
(243 | ) | — | |||||
|
Proceeds from (Repayments of) term loan
|
3,134 | (2,277 | ) | |||||
|
Proceeds from (Repayments of) Lines of credit, net
|
(18,538 | ) | 3,304 | |||||
|
Repayment of subordinated promissory note-related party
|
(2,231 | ) | (1,517 | ) | ||||
|
Repayment of acquisition loan, net
|
(800 | ) | — | |||||
| Option Expense | 785 | — | ||||||
|
Net cash used in financing activities
|
(18,901 | ) | (574 | ) | ||||
|
Net increase in cash
|
8,958 | 621 | ||||||
|
Cash at beginning of the period
|
3,082 | 2,461 | ||||||
|
Cash and restricted cash at end of period
|
12,040 | 3,082 | ||||||
|
Supplemental Disclosure of Cash Flow Information:
|
||||||||
|
Cash paid during the period for:
|
||||||||
|
Interest
|
1,582 | 1,999 | ||||||
|
Income taxes
|
861 | 585 | ||||||
|
Non-cash operating activities:
|
||||||||
|
Contingent earnout acquisition
|
250 | 64 | ||||||
|
Due to former owner
|
— | 740 | ||||||
| Non-cash investing activities: | ||||||||
| Airschott subordinated promissory note | — | 1,200 | ||||||
| Airschott contingent deferred consideration | — | 952 | ||||||
|
Non-cash financing activities:
|
||||||||
|
Dividends declared to preferred stockholders
|
384 | 328 | ||||||
| Extinguishment of related party debt | 540 | — | ||||||
| Year Ended September 30, | ||||||||
|
Service Type
|
2025 | 2024 | ||||||
|
Trucking
|
$ | 71,821 | $ | 73,193 | ||||
|
Ocean
|
49,371 | 40,567 | ||||||
|
Customs Brokerage and Other
|
33,751 | 19,445 | ||||||
|
Air
|
28,880 | 26,753 | ||||||
|
Total
|
$ | 183,823 | $ | 159,958 | ||||
| Year End September 30, | ||||||||
| 2025 | 2024 | |||||||
|
Finished goods
|
$ | 1,514 | $ | 1,860 | ||||
|
Work-in-process
|
1,424 | 1,236 | ||||||
|
Raw materials
|
1,679 | 1,884 | ||||||
|
Gross inventory
|
4,617 | 4,980 | ||||||
|
Less – reserve for inventory valuation
|
(410 | ) | (502 | ) | ||||
|
Inventory net
|
$ | 4,207 | $ | 4,478 | ||||
| September 30, | ||||||||||
| 2025 | 2024 | Life | ||||||||
|
Building and improvements
|
$ | 3,114 | $ | 3,083 | 12-30 years | |||||
|
Land and improvements
|
1,408 | 1,387 | Indefinite | |||||||
|
Furniture and Fixture
|
616 | 561 | 3-7 years | |||||||
|
Computer Equipment
|
910 | 854 | 3-5 years | |||||||
|
Machinery & Equipment
|
2,935 | 1,984 | 3-15 years | |||||||
|
Leasehold Improvements
|
916 | 906 | 3-5 years | |||||||
| 9,899 | 8,775 | |||||||||
|
Less Accumulated Depreciation
|
(3,928 | ) | (3,283 | ) | ||||||
| $ | 5,971 | $ | 5,492 | |||||||
| September 30, | ||||||||||
| 2025 | 2024 | Life | ||||||||
|
Customer relationships
|
$ | 37,725 | $ | 29,790 | 10-24 Years | |||||
|
Trademarks/names
|
5,110 | 4,661 | 1-20 Years | |||||||
|
Trademarks/names
|
521 | 521 | Indefinite | |||||||
|
Other
|
2,192 | 2,007 | 2-22 Years | |||||||
| 45,548 | 36,979 | |||||||||
|
Less: Accumulated Amortization
|
(14,550 | ) | (11,862 | ) | ||||||
| $ | 30,998 | $ | 25,117 | |||||||
| September 30, | ||||||||
| 2025 | 2024 | |||||||
|
Logistics
|
$ | 29,363 | $ | 22,494 | ||||
|
Life Sciences
|
8,485 | 6,785 | ||||||
|
Manufacturing
|
7,700 | 7,700 | ||||||
| 45,548 | 36,979 | |||||||
|
Less: Accumulated Amortization
|
(14,550 | ) | (11,862 | ) | ||||
| $ | 30,998 | $ | 25,117 | |||||
|
Fiscal Year 2026
|
$ | 3,316 | ||
|
Fiscal Year 2027
|
3,278 | |||
|
Fiscal Year 2028
|
3,235 | |||
|
Fiscal Year 2029
|
3,188 | |||
|
Fiscal Year 2030
|
2,910 | |||
|
Thereafter
|
14,550 | |||
| $ | 30,477 |
| September 30, | ||||||||
| 2025 | 2024 | |||||||
|
Logistics
|
$ | 17,768 | $ | 11,813 | ||||
|
Life Sciences
|
8,778 | 6,171 | ||||||
|
Manufacturing
|
5,046 | 5,046 | ||||||
|
Total
|
$ | 31,592 | $ | 23,030 | ||||
| September 30, | ||||||||
| 2025 | 2024 | |||||||
|
Total Debt
|
$ | 8,077 | $ | 4,304 | ||||
|
Less Current Portion
|
(911 | ) | (1,276 | ) | ||||
|
Long-term Portion
|
$ | 7,166 | $ | 3,028 | ||||
|
Fiscal Year 2026
|
$ | 911 | ||
|
Fiscal Year 2027
|
911 | |||
|
Fiscal Year 2028
|
911 | |||
|
Fiscal Year 2029
|
911 | |||
|
Fiscal Year 2030
|
4,433 | |||
| $ | 8,077 |
| September 30, | ||||||||
| 2025 | 2024 | |||||||
|
Total Subordinated Promissory Notes
|
$ | 2,940 | $ | 5,073 | ||||
|
Less Current Portion of Subordinated Promissory Notes
|
(1,174 | ) | (1,628 | ) | ||||
|
Long Term Portion of Subordinated Promissory Notes
|
$ | 1,766 | $ | 3,445 | ||||
| Total | ||||
|
2026
|
$
|
1,174 | ||
|
2027
|
883 | |||
|
2028
|
883 | |||
|
Total
|
$
|
2,940 | ||
| 2025 | 2024 | |||||||
|
Risk-free interest rate
|
3.45 | % | 4.63 | % | ||||
|
Expected option term in years
|
4.5 - 6.0 | 4.5 - 6.0 | ||||||
|
Expected volatility
|
49.4 | % | 58.2 | % | ||||
|
Dividend yield
|
— | % | — | % | ||||
|
Weighted average grant date fair value
|
$12.91 - $19.86 | $9.83 - 16.63 |
| Number of Options | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term (in years) | Aggregate Intrinsic Value (in thousands) | |||||||||||||
| Outstanding balance at September 30, 2024 | 49,993 | $ | 25.31 | 6.9 | $ | 705.34 | ||||||||||
| Granted | 12,500 | $ | 40.50 | 4.8 | $ | — | ||||||||||
| Expired | — | $ | — | — | $ | — | ||||||||||
| Outstanding balance at September 30, 2025 | 62,493 | $ | 28.35 | 6.5 | $ | 705.34 | ||||||||||
| Exercisable at September 30, 2025 | 27,493 | $ | 13.88 | 4.5 | $ | 608.34 |
| Number of Options | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term (in years) | Aggregate Intrinsic Value (in thousands) | |||||||||||||
| Outstanding Balance at September 30, 2024 | 35,607 | $ | 12.22 | 4.8 | $ | 375.02 | ||||||||||
| Exercised | (35,607 | ) | $ | 12.22 | — | $ | — | |||||||||
| Outstanding Balance at September 30, 2025 | — | $ | — | — | — |
| Year Ended September 30, | ||||||||
| 2025 | 2024 | |||||||
|
Income:
|
||||||||
|
Net income
|
$ | 5,657 | $ | 551 | ||||
|
Preferred stock dividends
|
(384 | ) | (328 | ) | ||||
|
Non-controlling interest dividends
|
(243 | ) | — | |||||
|
Net income available to common stockholders
|
$ | 5,030 | $ | 223 | ||||
|
Common Shares:
|
||||||||
|
Basic - weighted average common shares
|
1,186 | 1,186 | ||||||
|
Effect of dilutive stock options
|
19 | 20 | ||||||
|
Diluted - weighted average common stock
|
1,205 | 1,206 | ||||||
|
Income per Common Share:
|
||||||||
|
Basic -
|
||||||||
|
Net income
|
$ | 4.77 | $ | 0.46 | ||||
|
Preferred stock dividends
|
(0.33 | ) | (0.27 | ) | ||||
|
Non-controlling interest dividends
|
(0.20 | ) | — | |||||
|
Net income attributable to common stockholders
|
$ | 4.24 | $ | 0.19 | ||||
|
Diluted -
|
||||||||
|
Net income
|
$ | 4.69 | $ | 0.45 | ||||
|
Preferred stock dividends
|
(0.32 | ) | (0.27 | ) | ||||
|
Non-controlling interest dividends
|
(0.20 | ) | — | |||||
|
Net income available to common stockholders
|
$ | 4.17 | $ | 0.18 | ||||
| September 30, | ||||||||
| 2025 | 2024 | |||||||
|
Employee stock options (Note 10)
|
62,493 | 49,993 | ||||||
| 62,493 | 49,993 | |||||||
| Year Ended September 30, | ||||||||
| 2025 | 2024 | |||||||
|
Federal taxes at statutory rates
|
$ | 1,444 | $ | 230 | ||||
|
Permanent differences
|
(560 | ) | 109 | |||||
|
State and local taxes, net of Federal benefit
|
363 | 155 | ||||||
|
Other
|
(25 | ) | 49 | |||||
|
Total
|
$ | 1,222 | $ | 543 | ||||
| Year Ended September 30, | ||||||||
| 2025 | 2024 | |||||||
|
Current
|
$ | 1,479 | $ | 347 | ||||
|
Deferred
|
(257 | ) | 196 | |||||
|
Total
|
$ | 1,222 | $ | 543 | ||||
| 2025 | 2024 | |||||||
|
Deferred tax assets - net operating loss carryforwards
|
$ | 50 | $ | 48 | ||||
|
Lease liability
|
1,971 | 2,115 | ||||||
|
Other
|
854 | 744 | ||||||
|
Stock based compensation
|
467 | 445 | ||||||
|
Total deferred tax assets
|
3,342 | 3,352 | ||||||
|
Valuation allowance
|
— | — | ||||||
|
Total deferred tax assets net of valuation allowance
|
3,342 | 3,352 | ||||||
|
Deferred tax liabilities - depreciation and amortization
|
5,808 | 3,604 | ||||||
|
Prepaid expenses
|
263 | 237 | ||||||
|
Right of use assets
|
1,818 | 2,025 | ||||||
|
Total deferred tax liabilities
|
7,889 | 5,866 | ||||||
|
Net deferred tax liability
|
$ | (4,547 | ) | $ | (2,514 | ) |
|
For the year ended September 30, 2025 (in thousands)
|
Consolidated | Logistics | Life Sciences | Manufacturing | Corporate | |||||||||||||||
|
Revenues
|
$ | 207,443 | $ | 183,823 | $ | 14,126 | $ | 9,494 | $ | — | ||||||||||
|
Forwarding expenses and cost of revenues
|
142,450 | 134,760 | 3,261 | 4,429 | — | |||||||||||||||
|
Gross profit
|
64,993 | 49,063 | 10,865 | 5,065 | — | |||||||||||||||
|
Selling, general and administrative
|
55,871 | 38,680 | 8,402 | 3,253 | 5,536 | |||||||||||||||
|
Amortization of intangible assets
|
2,688 | — | — | — | 2,688 | |||||||||||||||
|
Income (loss) from operations
|
6,434 | 10,383 | 2,463 | 1,812 | (8,224 | ) | ||||||||||||||
|
Interest expense
|
2,073 | 1,370 | 433 | 270 | — | |||||||||||||||
|
Identifiable assets
|
170,753 | 82,942 | 12,126 | 3,682 | 72,003 | |||||||||||||||
|
Capital expenditures, net of disposals
|
$ | 590 | $ | 79 | $ | 492 | $ | 19 | $ | — |
|
For the year ended September 30, 2024 (in thousands)
|
Consolidated | Logistics | Life Sciences | Manufacturing | Corporate | |||||||||||||||
|
Revenues
|
$ | 183,184 | $ | 159,958 | $ | 13,154 | $ | 10,072 | $ | — | ||||||||||
|
Forwarding expenses and cost of revenues
|
124,800 | 117,501 | 2,638 | 4,661 | — | |||||||||||||||
|
Gross profit
|
58,384 | 42,457 | 10,516 | 5,411 | — | |||||||||||||||
|
Selling, general and administrative
|
52,327 | 37,057 | 7,216 | 3,129 | 4,925 | |||||||||||||||
|
Amortization of intangible assets
|
2,299 | — | — | — | 2,299 | |||||||||||||||
|
Income (loss) from operations
|
3,758 | 5,400 | 3,300 | 2,282 | (7,224 | ) | ||||||||||||||
|
Interest expense
|
2,318 | 1,667 | 367 | 284 | — | |||||||||||||||
|
Identifiable assets
|
110,610 | 42,495 | 11,230 | 4,162 | 52,723 | |||||||||||||||
|
Capital expenditures, net of disposals
|
$ | 1,003 | $ | 84 | $ | 911 | $ | 8 | $ | — | ||||||||||
| 2025 | 2024 | |||||||
|
Operating lease cost
|
$ | 2,542 | $ | 2,522 | ||||
|
Short-term lease cost
|
314 | 348 | ||||||
|
Total lease cost
|
$ | 2,856 | $ | 2,870 |
| Year End September 30, 2025 | ||||
|
2026
|
$ | 2,553 | ||
|
2027
|
2,416 | |||
|
2028
|
2,328 | |||
|
2029
|
1,030 | |||
|
2030
|
501 | |||
|
Thereafter
|
867 | |||
|
Total undiscounted loan payments
|
9,695 | |||
|
Less imputed interest
|
(1,271 | ) | ||
|
Total lease obligation
|
$ | 8,424 |
| September 30, | September 30, | |||||||
| 2025 | 2024 | |||||||
|
Balance at beginning of year
|
$ | 1,518 | $ | 1,573 | ||||
|
Fair value adjustments to Rubicon investment
|
3,113 | (55 | ) | |||||
|
Total
|
4,631 | 1,518 |
| Total fair value at September 30, 2025 | Quoted prices in active markets for identical assets (Level 1) | Significant other observable inputs (Level 2) | Significant unobservable inputs (Level 3) | |||||||||||||
|
Assets:
|
||||||||||||||||
|
Investment in Rubicon at fair value
|
$ | 4,631 | $ | 4,631 | $ | — | $ | — | ||||||||
|
Investment in other marketable securities
|
283 | 283 | — | — | ||||||||||||
| $ | 4,914 | $ | 4,914 | $ | — | $ | — | |||||||||
|
Liabilities:
|
||||||||||||||||
|
Contingent earnout liabilities
|
$ | 3,742 | $ | 1,143 | $ | — | $ | 2,599 | ||||||||
| $ | 3,742 | $ | 1,143 | $ | — | $ | 2,599 |
| Total fair value at September 30, 2024 | Quoted prices in active markets for identical assets (Level 1) | Significant other observable inputs (Level 2) | Significant unobservable inputs (Level 3) | |||||||||||||
|
Assets:
|
||||||||||||||||
|
Investment in Rubicon at fair value
|
$$ | 1,518 | $ | 1,518 | $ | — | $ | — | ||||||||
|
Investment in other marketable securities
|
56 | 56 | — | — | ||||||||||||
| $ | 1,574 | $ | 1,574 | $ | — | $ | — | |||||||||
| Liabilities: | ||||||||||||||||
|
Contingent earnout liabilities
|
$ | 3,381 | $ | 2,100 | $ | — | $ | 1,281 | ||||||||
| $ | 3,381 | $ | 2,100 | $ | — | $ | 1,281 |
| September 30, | ||||||||
| 2025 | 2024 | |||||||
|
Balance at beginning of year
|
$ | 3,381 | $ | 2,330 | ||||
|
Fair value of contingent consideration recorded in connection with business combinations
|
1,005 | 1,017 | ||||||
|
Earnout payment
|
(1,078 | ) | (740 | ) | ||||
|
Fair value adjustment of contingent earnout liabilities
|
434 | 774 | ||||||
|
Total
|
$ | 3,742 | $ | 3,381 | ||||
|
$8,612,733.94
|
Indianapolis, Indiana |
|
INDCO, INC.
|
||
|
ANTIBODIES INCORPORATED
|
||
|
PHOSPHOSOLUTIONS LLC
|
||
|
By:
|
||
|
Darren C. Seirer, Vice President
|
||
|
AVES LABS, INC.
|
||
|
IMMUNOCHEMISTRY TECHNOLOGIES LLC
|
||
|
IMMUNOBIOSCIENCE CORP.
|
||
|
By:
|
||
|
Darren C. Seirer, President
|
||
|
BIOSENSIS, LLC
|
||
|
By:
|
||
|
Name:
|
||
|
Title:
|
| $620,000.00 |
Indianapolis, Indiana
July 1, 2025
|
|
|
INDCO, INC.
|
||
|
|
ANTIBODIES INCORPORATED
|
||
|
|
PHOSPHOSOLUTIONS LLC
|
||
|
|
|
||
|
|
By:
|
||
|
|
|
Darren C. Seirer, Vice President | |
|
|
|
||
|
|
AVES LABS, INC.
|
||
|
|
IMMUNOCHEMISTRY TECHNOLOGIES LLC
|
||
|
|
IMMUNOBIOSCIENCE CORP.
|
||
|
|
|
||
|
|
By:
|
||
|
|
|
Darren C. Seirer, President | |
|
|
|
||
|
|
BIOSENSIS, LLC
|
||
|
|
|
||
|
|
By:
|
||
|
|
Name:
|
||
|
|
Title:
|
||
|
$3,000,000.00
|
Indianapolis, Indiana |
|
INDCO, INC.
|
||
|
ANTIBODIES INCORPORATED
|
||
|
PHOSPHOSOLUTIONS LLC
|
||
|
By:
|
||
|
Darren C. Seirer, Vice President
|
||
|
AVES LABS, INC.
|
||
|
IMMUNOCHEMISTRY TECHNOLOGIES LLC
|
||
|
IMMUNOBIOSCIENCE CORP.
|
||
|
By:
|
||
|
Darren C. Seirer, President
|
||
|
BIOSENSIS, LLC
|
||
|
By:
|
||
|
Name:
|
||
|
Title:
|
|
$7,000,000.00
|
Indianapolis, Indiana |
|
INDCO, INC |
||
|
ANTIBODIES INCORPORATED |
||
|
PHOSPHOSOLUTIONS LLC |
||
|
By:
|
||
|
Darren C. Seirer, Vice President
|
||
|
AVES LABS, INC.
|
||
|
IMMUNOCHEMISTRY TECHNOLOGIES LLC
|
||
|
IMMUNOBIOSCIENCE CORP.
|
||
|
By:
|
||
|
Darren C. Seirer, President
|
||
|
BIOSENSIS, LLC
|
||
|
By:
|
||
|
Name:
|
||
|
Title:
|
|
INDCO, INC.
|
||
|
ANTIBODIES INCORPORATED
|
||
|
PHOSPHOSOLUTIONS LLC
|
||
| By: | ||
|
Darren C. Seirer, Vice President
|
||
|
AVES LABS, INC.
|
||
|
IMMUNOCHEMISTRY TECHNOLOGIES LLC
|
||
|
IMMUNOBIOSCIENCE CORP.
|
||
| By: | ||
|
Darren C. Seirer, President
|
||
|
JANEL CORPORATION
|
||
| By: | ||
|
Darren C. Seirer, President
|
||
|
BIOSENSIS, LLC
|
||
|
By:
|
||
| Name: | ||
| Title: |
|
FIRST MERCHANTS BANK
|
||
|
By:
|
||
|
Jeff Pangburn, Vice President
|
||
| LENDER | ||
| SANTANDER BANK, N.A. | ||
| By: | ||
| Name: | ||
| Its: | ||
| BORROWERS | ||
| JANEL GROUP LLC, a New York limited liability company, as Borrower | ||
| By: | ||
| Name: | William J. Lally | |
| Its: | President | |
| EXPEDITED LOGISTICS AND FREIGHT SERVICES LLC, a Texas limited liability company, as Borrower | ||
| By: | ||
| Name: | William J. Lally | |
| Its: | Vice President | |
| ELFS BROKERAGE LLC, a Texas limited liability company, as Borrower | ||
| By: Janel Group LLC, its Manager1 | ||
| By: | ||
| Name: | William J. Lally | |
| Its: | President | |
|
|
AIRSCHOTT, INC., a Virginia corporation, as Borrower
|
|
|
|
|
|
|
|
By:
|
|
|
|
Name:
|
William J. Lally
|
|
|
Its:
|
Vice President
|
|
|
|
|
|
|
LOAN PARTY OBLIGORS
|
|
|
|
|
|
|
|
JANEL CORPORATION, a Nevada corporation, as Parent and an Obligor
|
|
|
|
|
|
|
|
By:
|
|
|
|
Name:
|
Joseph Ferrara
|
|
|
Its:
|
Chief Financial Officer
|
|
|
|
|
|
|
EXPEDITED LOGISTICS AND FREIGHT SERVICES LLC, an Oklahoma limited liability company, as an Obligor
|
|
|
|
|
|
|
|
By:
|
Expedited Logistics and Freight Services LLC, a
|
|
|
Texas limited liability company, its manager
|
|
|
|
|
|
|
|
By:
|
|
|
|
Name:
|
William J. Lally
|
|
|
Its:
|
Vice President
|
|
|
|
|
|
|
INTERLOG USA, INC., a Minnesota corporation, as the “New Borrower”
|
|
|
|
|
|
|
|
By:
|
|
|
|
Name:
|
|
|
|
Its: President
|
|
|
|
|
|
|
|
COMMERCE EXPRESS, INC., a Minnesota corporation, as the “New Borrower”
|
|
|
|
|
|
|
|
By:
|
|
|
|
Name:
|
|
|
|
Its: President
|
|

|
Janel Corporation
|
•
|
80 Eighth Avenue
|
•
|
New York, NY 10011
|
•
|
(212) 373-5895
|
•
|
janelcorp.com
|
Page 1 of 6 |

|
Janel Corporation
|
•
|
80 Eighth Avenue
|
•
|
New York, NY 10011
|
•
|
(212) 373-5895
|
•
|
janelcorp.com
|
Page 2 of 6 |

|
Janel Corporation
|
•
|
80 Eighth Avenue
|
•
|
New York, NY 10011
|
•
|
(212) 373-5895
|
•
|
janelcorp.com
|
Page 3 of 6 |

|
Janel Corporation
|
•
|
80 Eighth Avenue
|
•
|
New York, NY 10011
|
•
|
(212) 373-5895
|
•
|
janelcorp.com
|
Page 4 of 6 |

|
Janel Corporation
|
•
|
80 Eighth Avenue
|
•
|
New York, NY 10011
|
•
|
(212) 373-5895
|
•
|
janelcorp.com
|
Page 5 of 6 |

|
Janel Corporation
|
•
|
80 Eighth Avenue
|
•
|
New York, NY 10011
|
•
|
(212) 373-5895
|
•
|
janelcorp.com
|
Page 6 of 6 |
|
To the Board of Directors and Stockholders of
Janel Corporation and Subsidiaries
We consent to the incorporation by reference in Registration Statement on Form S-8 (No. 333-222791, 333-253400, and 333-264121) of Janel Corporation of our report dated December 5, 2025 with respect to our audit of the consolidated financial statements of Janel Corporation and Subsidiaries appearing in this Annual Report on Form 10-K of Janel Corporation as of and for the years ended September 30, 2025 and 2024.
/s/Prager Metis CPAs, LLC
Basking Ridge, New Jersey
December 5, 2025
|

|
Date: December 5, 2025
|
/s/ Darren C. Seirer
|
|
|
|
Darren C. Seirer
|
|
|
|
Board Chair, President and Chief Executive Officer
|
|
|
|
(Principal Executive Officer)
|
| Date: December 5, 2025 | /s/ Nathan C. Shandy | |
| Nathan C. Shandy | ||
| Chief Financial Officer, Treasurer and Secretary (Principal Financial Officer) |
|
Date: December 5, 2025
|
/s/ Darren C. Seirer
|
|
|
|
Darren C. Seirer
|
|
|
|
Board Chair, President and Chief Executive Officer
|
|
|
|
(Principal Executive Officer)
|
|
Date: December 5, 2025
|
/s/ Nathan C. Shandy
|
|
|
|
Nathan C. Shandy
|
|
|
|
Chief Financial Officer, Treasurer and Secretary
(Principal Financial Officer)
|